Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Standard Biotools (LAB) Intangibles (2016 - 2025)

Standard Biotools (LAB) has disclosed Intangibles for 12 consecutive years, with $28.1 million as the latest value for Q1 2025.

  • Quarterly Intangibles rose 13.16% to $28.1 million in Q1 2025 from the year-ago period, while the trailing twelve-month figure was $28.1 million through Mar 2025, up 13.16% year-over-year, with the annual reading at $29.0 million for FY2024, 1968.14% up from the prior year.
  • Intangibles for Q1 2025 was $28.1 million at Standard Biotools, down from $29.0 million in the prior quarter.
  • The five-year high for Intangibles was $37.0 million in Q1 2021, with the low at $1.4 million in Q4 2023.
  • Average Intangibles over 5 years is $20.6 million, with a median of $24.1 million recorded in 2024.
  • The sharpest move saw Intangibles tumbled 88.89% in 2023, then skyrocketed 1968.14% in 2024.
  • Over 5 years, Intangibles stood at $27.9 million in 2021, then crashed by 54.88% to $12.6 million in 2022, then crashed by 88.89% to $1.4 million in 2023, then surged by 1968.14% to $29.0 million in 2024, then decreased by 3.1% to $28.1 million in 2025.
  • According to Business Quant data, Intangibles over the past three periods came in at $28.1 million, $29.0 million, and $20.0 million for Q1 2025, Q4 2024, and Q3 2024 respectively.